Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia - Physicians in Georgia and Neighboring Countries will be Trained in Emergency Use of Intravenous ZYESAMI!...
Transforms Relief into a fully integrated commercial-stage biopharmaceutical company Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches Provides ...
GENEVA, SWITZERLAND / ACCESSWIRE / June 16, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today t...
GENEVA, SWITZERLAND / ACCESSWIRE / June 2, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today th...
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure - ZYESAMI™ is the First ...
Relief Therapeutics (RLFTF) has appointed Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer ((COO)), effective June 1, 2021. Dr. Taneli Jouhikainen has over 25 years of life sciences expertise. He joins Relief from Savara, a Nasdaq-listed clinical stage b...
GENEVA, SWITZERLAND / ACCESSWIRE / May 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorders...
Acer Therapeutics (ACER) said that it plans to submit an NDA for its Urea Cycle Disorders ((UCDs)) treatment ACER-001 to the U.S. FDA in the third-quarter of this year, following a pre-NDA meeting with the health regulator.ACER-001 is a proprietary immediate release powder...
NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with signif...
Relief Therapeutics Holding (RLFTF) provides an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) being developed for the treatment of urea cycle disorders (UCDs).UCDs are a group of rare genetic metabolic disorders which can lead to an ex...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...